Geulah Livshits
Stock Analyst at Chardan Capital
(3.57)
# 844
Out of 4,967 analysts
220
Total ratings
41.82%
Success rate
8.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $219 → $216 | $146.93 | +47.01% | 13 | Aug 22, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.27 | +236.39% | 21 | Aug 20, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $20 → $15 | $4.86 | +208.64% | 10 | Aug 15, 2025 | |
| MGX Metagenomi | Maintains: Buy | $12 → $11 | $1.78 | +517.98% | 7 | Aug 15, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $50 → $60 | $51.83 | +15.77% | 2 | Aug 15, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $5.94 | +118.86% | 13 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $5.42 | +177.01% | 8 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $9 → $10 | $2.88 | +247.22% | 14 | Aug 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $6.11 | +309.17% | 12 | Aug 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $11.48 | +422.65% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $3.16 | +216.46% | 6 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $1.39 | +764.37% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $2.21 | +807.03% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $1.05 | +757.14% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 | $52.28 | +56.86% | 15 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $7.01 | +1,611.84% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.47 | +1,179.86% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.56 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.26 | +465.13% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $5.42 | +361.25% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.44 | +733.33% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $23.62 | +780.61% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.25 | +1,180.00% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $9.23 | +875.08% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.57 | +12.04% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.99 | +903.34% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $9.42 | +91.18% | 1 | Oct 27, 2020 |
Krystal Biotech
Aug 22, 2025
Maintains: Buy
Price Target: $219 → $216
Current: $146.93
Upside: +47.01%
Rocket Pharmaceuticals
Aug 20, 2025
Maintains: Buy
Price Target: $11
Current: $3.27
Upside: +236.39%
Lexeo Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $20 → $15
Current: $4.86
Upside: +208.64%
Metagenomi
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.78
Upside: +517.98%
Palvella Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $50 → $60
Current: $51.83
Upside: +15.77%
Immuneering
Aug 14, 2025
Maintains: Buy
Price Target: $13
Current: $5.94
Upside: +118.86%
Solid Biosciences
Aug 14, 2025
Maintains: Buy
Price Target: $15
Current: $5.42
Upside: +177.01%
Taysha Gene Therapies
Aug 12, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $2.88
Upside: +247.22%
4D Molecular Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $25
Current: $6.11
Upside: +309.17%
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $11.48
Upside: +422.65%
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.16
Upside: +216.46%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $1.39
Upside: +764.37%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.21
Upside: +807.03%
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $1.05
Upside: +757.14%
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $52.28
Upside: +56.86%
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $7.01
Upside: +1,611.84%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.47
Upside: +1,179.86%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.26
Upside: +465.13%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $5.42
Upside: +361.25%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.44
Upside: +733.33%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $23.62
Upside: +780.61%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.25
Upside: +1,180.00%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $9.23
Upside: +875.08%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.57
Upside: +12.04%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.99
Upside: +903.34%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $9.42
Upside: +91.18%